Haemonetics Corporation

Healthcare · Medical Devices

105.30$ -0.7% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Haemonetics Corporation (HAE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 339 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement HAE
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	220	228	228	211	225	234	234	229	242	247	249	238	253	259	238	196	209	240	225	229	240	260	265	261	297	305	304	311	318	336	343	336	346	349	331	321	327	339	346	339	1,352
Cost of Revenue	116	127	146	119	121	123	129	146	130	136	138	122	125	131	122	105	104	120	114	118	117	121	111	119	140	147	140	144	148	151	154	157	154	149	149	130	144	148	148	137	576
Gross Profit	104	101	82	92	105	111	104	83	112	111	111	116	127	128	116	91	106	120	111	110	123	138	154	142	158	159	164	167	171	185	189	179	191	200	182	192	183	191	198	203	776
Research & Development	8.3	8.5	19	8.2	7.5	12	11	9.4	8.6	9.0	8.7	7.5	7.4	7.0	17	7.8	6.8	7.5	19	13	11	10	22	11	11	13	24	13	13	13	24	14	14	16	16	16	15	14	14	16	59
Selling, General & Administrative	71	71	69	64	73	66	76	69	75	72	74	70	65	70	34	64	2.2	0.1	57	91	76	78	92	92	92	95	88	93	105	112	108	108	107	106	115	111	102	107	121	119	448
Total Operating Expenses	79	80	140	75	80	110	90	78	86	83	87	129	78	87	90	79	47	80	132	109	98	103	135	111	111	115	129	114	135	139	159	140	140	141	130	138	116	122	147	145	530
Operating Income	25	21	-58	17	24	1.0	14	5.3	26	28	24	-13	50	41	26	12	59	40	-21	1.4	25	36	19	31	47	43	35	54	35	46	30	40	52	59	51	54	67	70	51	57	246
Interest Expense	2.0	2.3	1.7	1.4	1.4	0.8	1.0	2.0	3.0	2.9	2.0	4.4	4.7	3.1	4.0	3.7	3.8	3.1	6.2	4.4	4.6	4.3	3.9	5.3	5.7	1.1	2.6	2.1	2.5	1.9	6.5	7.0	7.0	9.1	0.6	4.1	7.2	8.1	5.4	9.9	31
Pre-Tax Income	23	19	-59	23	23	0.2	13	3.3	23	25	22	-18	45	38	22	13	55	37	5.3	-3.0	20	31	15	25	41	42	33	52	33	44	23	47	45	50	71	45	51	60	-28	48	130
Income Tax Expense	3.0	3.5	-8.0	3.1	2.8	6.8	1.4	6.1	4.3	7.2	1.0	-9.2	7.6	7.9	4.3	2.5	6.9	5.5	16	1.4	5.1	8.2	5.6	5.6	7.9	9.3	3.2	11	7.9	13	3.0	8.3	11	12	13	11	13	15	-8.3	15	34
Net Income	20	15	-51	20	20	-6.5	12	-2.8	19	18	21	-8.5	37	30	18	11	48	32	-11	-4.5	15	23	9.7	20	33	33	29	41	25	31	20	38	34	37	58	34	39	45	-20	33	96
EBITDA	48	43	18	46	46	23	37	32	51	56	54	58	63	64	73	31	51	60	55	17	52	60	56	53	71	67	62	77	66	83	68	80	89	95	99	94	87	95	4.3	75	261

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings